Drug Database
HE

hepatitis-B vaccine

✓ Approved

Merck & Co. · · 疫苗

什么是 hepatitis-B vaccine?

hepatitis-B vaccine 是一种疫苗,由Merck & Co.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intradermal Injection。

药物档案

公司Merck & Co.
药物类别疫苗
给药途径Injectable (Others), Intradermal Injection
状态Approved

作用机制

分子靶点

hepatitis-B vaccine 作用于 1 个分子靶点:

(S)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

相关研究文献

PubMedBioinformatics and biology insights2026-11-18

Formulation of a Novel NS5A- and NS5B-Based Chimeric Vaccine Against Hepatitis C Virus: An Artificial Intelligence-Supported Approach.

Niknam Maryam M, Zohrabzadeh Maryam M, Hahashempour Ava A, Honari Jahromi Ali A et al.

We aimed to design a multiepitope vaccine against hepatitis C virus (HCV) with the potential to elicit broad protective immunity against diverse HCV genotypes through computational design.Method: One hundred sequences of the most widespread subtypes of HCV were retrieved from the Los Alamos National Laboratory database, and consensus sequences of the NS5A and NS5B proteins were generated to construct an efficient vaccine for human use. Numerous B-cell lymphocyte, cytotoxic T-lymphocyte and helper T-lymphocyte epitopes located in the conserved domains of HCV proteins and similar in human and mouse alleles were evaluated criteria for use in the vaccine construct. Population coverage analysis identified that substantial parts of the worldwide population carry epitopes and their corresponding alleles within their genome, which confirms that the vaccine candidate is an effective agent against this lethal disease. Codon optimization and in silico cloning of eukaryotic and prokaryotic vectors validated the strong expression of the vaccine construct in the host systems. Molecular docking analysis revealed favorable binding affinities between the vaccine construct and toll-like receptors, which confirmed the vaccine's capacity to induce robust and stable immune responses against the hepatitis C virus. We incorporated new bioinformatic methods to design multiepitope vaccine against HCV. The development of a vaccine targeting multi genotypes of HCV could potentially provide for long-term protection against infection and may mitigate the risk of drug resistance across various genotypes and subtypes. Current research emphasizes the need for a vaccine that can elicit comprehensive immune responses, including both neutralizing antibodies and T-cell responses, to effectively address the genetic diversity of the virus. Future experimental studies are essential to validate predicted immunogenicity, structural stability, and protective efficacy before clinical consideration.

PMID 43047676
阅读全文 →
PubMedJournal of the European Academy of Dermatology and Venereology : JEADV2026-11-18

STI screening and hepatitis B vaccination needs among male adolescents in judicial detention.

Turri Brufatto João Paulo JP, Maciel Marina Gagheggi MG, Pattaro Raquel Duarte RD, Corrêa Raphaela Espanha RE et al.

PMID 43049562
阅读全文 →
PubMedInternational health2026-11-18

Three-dose coverage may conceal a perinatal hepatitis B prevention gap in Ethiopia.

Yılmaz Ercan E, Topal Erdem E

PMID 43046896
阅读全文 →
PubMedSage open chronic disease2026-11-18

HepPlus: Protocol for a prospective multicenter observational study of a web-based platform to support Hepatitis B and C management in Thailand.

Chairuengjitjaras Pitchaya P, Sudchit Ketsarapohn K, Boonsiripiyachok Nattapat N, Tangkijvanich Pisit P

Hepatitis B and C are chronic infections requiring lifelong monitoring and care coordination across primary, secondary, and tertiary care. In Thailand, these conditions remain leading causes of liver-related morbidity and mortality, yet fragmented health information systems and limited interoperability between facilities cause many patients to be lost to follow-up, highlighting the need for digital solutions that support continuity of care, clinical decision-making, and disease surveillance. This study describes the protocol for the development and pilot implementation of HepPlus, a web-based application designed to 1 serve as a national e-registry for hepatitis B virus (HBV) and hepatitis C virus (HCV) 2 support healthcare providers in treatment decisions through embedded clinical decision support (CDS); and 3 improve care coordination through standardized documentation and secure communication. This is a prospective, multicenter, non-randomized observational study conducted across three sequential phases (community screening, primary and secondary care, and tertiary care) within Thailand's Sixth Regional Health Area. In Phase 1, nurse practitioners at primary care clinics will screen patients using rapid HBV/HCV tests and register confirmed cases into the HepPlus platform. In Phase 2, patients will be managed at district or general hospitals, with physicians completing the modified Healthcare Systems Usability Scale (HSUS) at six months and joining focus groups at month nine. In Phase 3, patients with complex conditions referred to tertiary hospitals will be managed by subspecialists, who will complete the HSUS at month nine and join focus groups at month twelve. Primary and secondary outcomes include platform usability (patient safety, workflow integration, and user control), patient retention, and the proportion of patients receiving appropriate treatment, analyzed using descriptive statistics and thematic analysis. HepPlus has the potential to strengthen hepatitis B and C care through standardized documentation, clinical decision support, and improved care coordination. Its web-based design supports use across diverse settings and may contribute to real-time surveillance and digital health efforts. Integration with electronic health record systems remains a key area for future work.

PMID 43047925
阅读全文 →
PubMedACG case reports journal2026-11-18

Transplant-Free Recovery in Hepatitis B-Associated Acute Liver Failure Presenting With Cerebral Edema and Decerebrate Posturing.

Gupta Udita U, Ortega Macias Alan A, Akepati Prithvi Reddy PR, Estes Derek D et al.

Acute liver failure (ALF) complicated by cerebral edema and intracranial hypertension carries a high mortality. We report a 31-year-old woman with acute hepatitis B-associated ALF who presented with grade IV encephalopathy, decerebrate posturing, and diffuse cerebral edema in the setting of severe hyperammonemia (ammonia 296 μmol/L). Invasive intracranial pressure monitoring was deferred because of profound coagulopathy. Despite a Model for End-Stage Liver Disease score of 29 and ineligibility for liver transplantation due to active substance use, she achieved complete neurologic and hepatic recovery with aggressive medical management. This case highlights that severe cerebral edema in ALF may be reversible with early recognition and multidisciplinary intensive care management, even in patients who are not transplant candidates.

PMID 43048305
阅读全文 →
PubMedJournal of nanobiotechnology2026-11-18

Baculovirus-based production of virus-like particles for avian influenza: development, immunogenicity, and cross-protection against H5 and H7 AIVs.

He Yanjuan Y, Dong Yajing Y, Kong Dexin D, Chen Huixin H et al.

The persistent threat of H5 and H7 highly pathogenic avian influenza (HPAI) necessitates effective broad-spectrum vaccines. This study systematically evaluated the immunogenicity and protective efficacy of H5N6 virus-like particle (H5N6-VLP) vaccine and subsequently developed a trivalent VLP vaccine (H5N6-H5N8-H7N9-VLP) using the baculovirus expression system (BEVS). Production of H5N6-VLP was optimized at a multiplicity of infection (MOI) of 0.1 to achieve efficient assembly. The H5N6-VLP vaccine induced potent immune responses in specific-pathogen-free (SPF) chickens, providing 100% protection against homologous H5N6-GD154 virus when the HA titer reached 9 log2. Compared with traditional inactivated vaccines, the H5N6-VLP vaccine induced faster humoral immune responses and higher CD8⁺ T cell proportions. The HI seroconversion rate was 30% on day 7 post-immunization (0% for inactivated vaccine), reached 100% by day 10, while it was only 80% on day 14 for the inactivated vaccine. Furthermore, the protective efficacy of the H5N6-VLP vaccine was associated with increased IFN‑γ expression and elevated proportions of B cells and CD8⁺ T cells. Although both vaccines provided complete homologous protection, the H5N6-VLP vaccine showed better cross-protection against the heterologous H5N1-D889 strain (70% vs. 40%). A delayed challenge experiment further demonstrated that the H5N6-VLP vaccine induced durable immunity, with HI titers remaining above the protective threshold and 100% protection against homologous challenge at 8 weeks post-immunization. Based on these findings, a trivalent H5N6-H5N8-H7N9-VLP vaccine was developed. The trivalent vaccine induced substantial antibody responses and provided complete protection against parental and circulating strains, with efficacy comparable to a commercial inactivated vaccine and no detectable antigenic interference between components. Our findings highlight the potential of the BEVS-derived H5N6-VLP vaccine, particularly its early antibody induction, which allows rapid flock protection during acute HPAI outbreaks, and its cross-reactivity against heterologous strains. Furthermore, the trivalent vaccine formulation extends the potential application of this VLP platform for broad-spectrum HPAI control.

PMID 43046102
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多hepatitis-B vaccine